levomefolic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: levomefolic acid
• 英文别名: (6S)-5-methyltetrahydrofolic acid；(6S)-5-methyl-THF；N-(5-methyl-5,6,7,8-tetrahydro-pteroyl)-glutamic acid；5-methyl-(6S)-tetrahydrofolic acid；2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
• 化学式: C₂₀H₂₅N₇O₆
• 分子量: 459.462
• InChiKey: ZNOVTXRBGFNYRX-UEWDXFNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  199
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  levomefolic acid 在 水 、 sodium hydroxide 作用下， 以 乙醇 、 异丙醇 为溶剂， 以94.5%的产率得到disodium 5-methyl-(6S)-tetrahydrofolic acid
  参考文献：
  名称：

  WO2018/178144

  摘要：

  公开号：

文献信息

• [EN] COMPOSITIONS CONTAINING TANAPROGET AND NATURAL ESTROGENS<br/>[FR] COMPOSITION CONTENANT DU TANAPROGET ET DES ŒSTROGÈNES NATURELS
  申请人：TEVA WOMENS HEALTH INC

  公开号：WO2014159377A1

  公开（公告）日：2014-10-02

  The present invention provides compositions containing Tanaproget and a natural estrogen. In one embodiment, the natural estrogen is 17β-estradiol or E4. Also provided are drug delivery devices and kits containing these compounds and compositions and methods of contraception, methods of hormone replacement therapy, and treating or a preventing hormone-dependent gynecological disease using the compositions, kits and drug delivery devices described herein.

  本发明提供了含有坦普罗吉特和天然雌激素的组合物。在一个实施例中，天然雌激素是17β-雌二醇或E4。还提供了药物输送装置和包含这些化合物和组合物的套装，以及使用本文描述的组合物、套装和药物输送装置进行避孕、激素替代疗法、治疗或预防激素依赖性妇科疾病的方法。
• [EN] CRYSTALLINE BINARY SODIUM SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID WITH ORGANIC BASES<br/>[FR] SELS DE SODIUM BINAIRE CRISTALLINS D'ACIDE 5-MÉTHYL-(6S)-TÉTRAHYDROFOLIQUE AVEC DES BASES ORGANIQUES
  申请人：MERCK PATENT GMBH

  公开号：WO2018178142A1

  公开（公告）日：2018-10-04

  The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the sodium is from :0.5 to 1:1.5 and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the organic base is 1:0.5 to 1:1.5 and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.

  本发明涉及5-甲基-(6S)-四氢叶酸的结晶盐，包括(i) 5-甲基-(6S)-四氢叶酸，(ii) 钠和(iii) 具有pKa值在6到11之间的有机碱；其中5-甲基-(6S)-四氢叶酸与钠的物质摩尔比为：0.5至1:1.5，5-甲基-(6S)-四氢叶酸与有机碱的物质摩尔比为1:0.5至1:1.5，以及它们的水合物和/或溶剂合物，以及获得它们的方法。
• [EN] CRYSTALLINE SALT COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND 4-(2-HYDROXYETHYL)-MORPHOLINE<br/>[FR] SEL CRISTALLIN COMPRENANT DE L'ACIDE 5-MÉTHYL-(6S)-TÉTRAHYDROFOLIQUE ET DE LA 4-(2-HYDROXYÉTHYL)-MORPHOLINE
  申请人：MERCK PATENT GMBH

  公开号：WO2020007834A1

  公开（公告）日：2020-01-09

  The present inventionrefers to a crystalline salt comprising5-methyl-(6S)- tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of -methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to :2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

  本发明涉及一种结晶盐，包括5-甲基-(6S)-四氢叶酸和4-(2-羟乙基)-吗啉，其中-甲基-(6S)-四氢叶酸与4-(2-羟乙基)-吗啉的摩尔比为1:0.3到2.0（以摩尔比计算），以及其水合物和/或溶剂合物，以及获得该结晶盐的方法。
• [EN] FOLATE SALTS FOR MEDICAL USE<br/>[FR] SELS DE FOLATE À USAGE MÉDICAL
  申请人：APROFOL AG

  公开号：WO2019063236A1

  公开（公告）日：2019-04-04

  The invention relates to amorphous folate salt. The salt consists of a folate anion and an organic cation. The folate anion is selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-methyl- (6S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-Methylene-(6R)- tetrahydrofolic acid, and its oxidized derivatives JK12A and Mefox, and the cation is an organic compound selected from the group arginine, choline, acetylcholine, 1,1-dimethyl-biguanidin phenylethylbiguanidin, betaine-methylester and dimethylanninoethanol. The cation is an organic compound with a complementary pharmacological activity.

  该发明涉及非晶态叶酸盐。该盐由叶酸阴离子和有机阳离子组成。叶酸阴离子选自5-甲酰-(6S)-四氢叶酸、10-甲酰-(6R)-四氢叶酸、5-甲基-(6S)-四氢叶酸、(6S)-四氢叶酸、5,10-亚甲基-(6R)-四氢叶酸及其氧化衍生物JK12A和Mefox等，阳离子选自精氨酸、胆碱、乙酰胆碱、1,1-二甲基-双胍苯乙双胍、甜菜碱甲酯和二甲基氨基乙醇等有机化合物。该阳离子是具有互补药理活性的有机化合物。
• [EN] CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND AMINO ACID ETHYL ESTERS<br/>[FR] SELS CRISTALLINS D'ACIDE 5-MÉTHYL-(6S)-TÉTRAHYDROFOLIQUE ET D'ESTERS ÉTHYLIQUES D'ACIDES AMINÉS
  申请人：MERCK PATENT GMBH

  公开号：WO2020007843A1

  公开（公告）日：2020-01-09

  The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethylester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

  本发明涉及一种晶体盐，包括5-甲基-(6S)-四氢叶酸和氨基酸乙酯，如L-苯丙氨酸乙酯或L-蛋氨酸乙酯，其中5-甲基-(6S)-四氢叶酸与氨基酸乙酯的摩尔比为1:0.3至1:3.0（以摩尔比计算），以及其水合物和/或溶剂合物，以及获得该晶体盐的方法。